News and Events

FOR IMMEDIATE RELEASE: BURLINGTON, MA., — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA).

LEXINGTON, MA, April 26, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, announced the appointment of John Tucker as president and chief executive officer, effective immediately. Mr. Tucker was also elected to the board of directors of scPharmaceuticals.

LEXINGTON, Mass., January 24, 2017 /PRNewswire/ – scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN). HFN is a clinical research initiative funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The primary goal of the HFN is to conduct multiple clinical trials to evaluate treatments and strategies to improve management of acute and chronic heart failure.

Funding supports preparation for commercial introduction of Furoscix™ and further advancement of the sc2Wear™ drug delivery platform.

FOR IMMEDIATE RELEASE: Lexington, MA, December 20, 2016 /PRNewswire — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it entered into a long-term commercial supply agreement and associated tools manufacturing agreement with Raumedic AG (Helmbrechts, Germany) for the single-use component of its sc2WearTM Infusor. scPharmaceuticals is developing […]

— Complete bioavailability after subcutaneous administration of ceftriaxone — Equivalent antimicrobial coverage (time over MIC) to standard intravenous administration FOR IMMEDIATE RELEASE: Lexington, MA., October 31, 2016 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the presentation of study results at IDWeek 2016 in New Orleans, Louisiana. […]

– Complete bioavailability and equivalent diuresis after subcutaneous administration under experimental conditions – Equivalent diuresis when compared to high dose IV in heart failure patients in need of treatment of fluid overload   FOR IMMEDIATE RELEASE: LEXINGTON, MA., September 19, 2016 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous […]

FOR IMMEDIATE RELEASE: LEXINGTON, MA., July 12, 2016 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Jack A. Khattar has been appointed to scPharmaceuticals’ Board of Directors. Jack A. Khattar is the founder of Supernus Pharmaceuticals (NASDAQ:SUPN) and has served as president and Chief […]

COO and CFO appointments to prepare the company for product introductions in 2017   FOR IMMEDIATE RELEASE:  LEXINGTON, Mass., March 28, 2016 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, today announced two executive appointments reflecting the evolution of the company from a development-oriented company to a commercially-focused […]

Antibacterial coverage (time over MIC) equivalent to coverage following standard intravenous administration. Novel route of administration is free from common and serious risks associated with intravenous infusion lines and deep intramuscular injections. FOR IMMEDIATE RELEASE:  LEXINGTON, Mass., March 2, 2016 /PRNewswire/ — scPharmaceuticals, Inc., announced today that the pivotal trial for its ceftriaxone program met […]

FOR IMMEDIATE RELEASE:  – Sensile Medical wins as Innovation Leader for micropump at core of sc2Wear Patch Pump– LEXINGTON, MA. November 23, 2015– scPharmaceuticals, Inc. today announced that its strategic partner, Sensile Medical, was awarded the prestigious Swiss Technology Award in the category “Innovation Leader.” The prize is the most important distinction for innovation and technology […]

FOR IMMEDIATE RELEASE: Program aims to develop a new method of delivering trusted antibiotic without risk or costs associated with daily intravenous infusions. LEXINGTON, Mass., November 10, 2015 /PRNewswire/ — scPharmaceuticals, Inc., announced today that it has commenced its pivotal trial of subcutaneous administration of the antibiotic ceftriaxone for use with the sc2Wear Patch Pump. […]

FOR IMMEDIATE RELEASE: – Complete (100%) bioavailability after subcutaneous administration when compared with intravenous administration – – Diuresis at 8 and 24 hours was equivalent to diuresis following standard intravenous administration – U.S. and EU regulatory filings anticipated in 2016 – LEXINGTON, MA. – scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics […]

FOR IMMEDIATE RELEASE: Novel formulation and proprietary patch pump would offer a new and different option for the management of fluid overload in heart failure. LEXINGTON, Mass. /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that it has commenced its pivotal trial of its investigational proprietary […]

FOR IMMEDIATE RELEASE: LEXINGTON, Mass. /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that it has elected Dorothy A. Coleman to its board of directors and that it has appointed Brian Piekos as Chief Financial Officer. Ms. Coleman, a 30-year veteran of the healthcare industry, is […]

FOR IMMEDIATE RELEASE: LEXINGTON, Mass. /PRNewswire/ – scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Pieter Muntendam, President, CEO and founder of scPharmaceuticals, will present at Leerink Global Healthcare Conference in New York, NY on February 11, 2015. Dr. Muntendam will provide an update on the company […]

FOR IMMEDIATE RELEASE: LEXINGTON, Mass. /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Leonard D. Schaeffer has been appointed to scPharmaceutical’s board of directors. Mr. Schaeffer was the founding Chairman and CEO of WellPoint, the nation’s largest health benefits company by membership. He is currently the […]

FOR IMMEDIATE RELEASE: Boston, MA – scPharmaceuticals LLC today announced that it has entered into a strategic partnership and product development agreement with Sensile Medical Holding AG of Zug, Switzerland to develop an innovative new therapeutic option for patients with heart failure.  The terms of the agreement were not disclosed. The drug-device combination uses the […]

Series A co-led by 5AM Ventures and Lundbeckfond Ventures FOR IMMEDIATE RELEASE Lexington, MA – scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that it has closed a $16.0 million Series A venture financing round co-led by 5AM Ventures and Lundbeckfond Ventures. Proceeds from the financing will […]